Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Inventory (2016 - 2025)

Vanda Pharmaceuticals' Inventory history spans 13 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Inventory rose 7.3% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 7.3%, while the annual FY2025 figure was $1.9 million, 7.3% up from the prior year.
  • Inventory for Q4 2025 was $1.9 million at Vanda Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Across five years, Inventory topped out at $10.7 million in Q1 2023 and bottomed at $902000.0 in Q3 2021.
  • The 5-year median for Inventory is $1.8 million (2024), against an average of $3.8 million.
  • The largest annual shift saw Inventory skyrocketed 809.76% in 2022 before it tumbled 85.92% in 2024.
  • A 5-year view of Inventory shows it stood at $8.3 million in 2021, then tumbled by 85.53% to $1.2 million in 2022, then skyrocketed by 754.69% to $10.2 million in 2023, then plummeted by 83.09% to $1.7 million in 2024, then grew by 7.3% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Inventory are $1.9 million (Q4 2025), $2.0 million (Q3 2025), and $2.2 million (Q2 2025).